about
Heparin versus placebo for non-ST elevation acute coronary syndromesCost-effectiveness of optimal use of acute myocardial infarction treatments and impact on coronary heart disease mortality in China.The non-anticoagulant heparin-like K5 polysaccharide derivative K5-N,OSepi attenuates myocardial ischaemia/reperfusion injury
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
Heparin versus placebo for acute coronary syndromes
@ast
Heparin versus placebo for acute coronary syndromes
@en
Heparin versus placebo for acute coronary syndromes
@en-gb
Heparin versus placebo for acute coronary syndromes
@nl
type
label
Heparin versus placebo for acute coronary syndromes
@ast
Heparin versus placebo for acute coronary syndromes
@en
Heparin versus placebo for acute coronary syndromes
@en-gb
Heparin versus placebo for acute coronary syndromes
@nl
prefLabel
Heparin versus placebo for acute coronary syndromes
@ast
Heparin versus placebo for acute coronary syndromes
@en
Heparin versus placebo for acute coronary syndromes
@en-gb
Heparin versus placebo for acute coronary syndromes
@nl
P2093
P2860
P1476
Heparin versus placebo for acute coronary syndromes
@en
P2093
Brian H Rowe
Kirk Magee
Samuel G Campbell
P2860
P356
10.1002/14651858.CD003462.PUB2
P50
P577
2008-04-23T00:00:00Z